Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03937817 |
Recruitment Status :
Recruiting
First Posted : May 6, 2019
Last Update Posted : January 27, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Background:
Blood disorders like sickle cell disease and malaria affect many people around the world. Researchers want to learn more about blood disorders. To do this, they need to collect biological samples from people with blood disorders. They also need to collect samples from healthy people.
Objective:
To collect samples to use for research on blood disorders.
Eligibility:
People ages 18-70 who have blood disorders. Healthy volunteers without blood disorders are also needed.
Design:
Participants will be screened with a medical history, physical exam, and blood and urine tests.
Participants will give one or more samples. They will give them over 5 years. They can choose not to give any of the samples:
Saliva: Participants will spit into a tube. They may also have the inside of their mouth swabbed.
Urine: Participants will urinate into a cup.
Blood: Blood will be taken through a needle in the participant s arm.
Fat samples: An area on the participant s belly or buttock will be numbed. A small cut will be made into the skin and a small piece of fat removed.
Mucus and cells from the lungs: The participant will be sedated. A flexible tube will be inserted through the nose or mouth into the lung airways. These participants will also have a physical exam, chest x-ray, and heart tests after the procedure.
...
Condition or disease |
---|
Alpha and Beta Thalassemia Sickle Cell Disease Malaria Human Physiology |
The Physiology Unit of the Laboratory of Malaria and Vector Research studies the role of globin variants in erythroid and non-erythroid tissues. We hope to better understand the mechanism(s) through which alpha and beta globin variants impact malaria, sickle cell disease, or other diseases involving inflammation or endothelial dysfunction.
The collection of human specimens from healthy volunteers and patients with malaria, sickle cell disease, or other diseases involving inflammation or endothelial dysfunction is necessary for the development of laboratory and physiological assays to further basic and clinical research studies. This protocol defines the purposes for which specimens will be collected and establishes general conditions under which sample collection will be performed. Development of assays and our research into the roles of alpha and beta globin in normal human physiology, as well as in the pathogenesis of malaria and sickle cell disease, requires laboratory analysis of saliva/buccal swab, urine, blood, adipose tissue, bronchial brushing, and/or bronchoalveolar lavage specimens from human volunteers.
Study Type : | Observational |
Estimated Enrollment : | 300 participants |
Observational Model: | Other |
Time Perspective: | Prospective |
Official Title: | Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants |
Actual Study Start Date : | September 25, 2019 |
Estimated Primary Completion Date : | March 31, 2029 |
Estimated Study Completion Date : | March 31, 2029 |

Group/Cohort |
---|
1
Healthy volunteers and patients with hematologic and hemolytic diseases, including alpha and beta globin variants, sickle cell disease, malaria, or other diseases involving inflammation or endothelial dysfunction.
|
- Collect biological specimens (saliva, urine, blood, adipose tissue, bronchial brushing, and/or BAL) [ Time Frame: Throughout study ]Development and optimization of scientific assays and research of globin variants, sickle cell disease, malaria, or other related diseases.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
-
PARTICIPANT INCLUSION CRITERIA:
- Aged 18-70 years.
- Able to provide informed consent.
- Willing to allow biological samples to be stored for future research.
- Willing to provide one or more of the following tissues: saliva, urine, blood, adipose tissue, bronchial brushing, and/or BAL samples.
-
Willing to allow genetic testing on collected biological samples.
PARTICIPANT EXCLUSION CRITERIA:
- Exclusion Criteria for Saliva Sample Collection Only
Any condition that, in the opinion of the principal investigator (PI), contraindicates participation in this study, will be cause for exclusion. However, there are no explicit exclusion criteria for the collection of saliva samples only.
-Exclusion Criteria for All Other Participants
The following exclusion criteria apply to all participants who will provide any of the following samples in-person at the NIH CC: urine, blood, adipose tissue, bronchial brushing, and/or BAL samples:
- Pregnancy.
- Positive testing for hepatitis B virus, hepatitis C virus, or HIV (as determined by serum screening tests or relevant viral quantitative studies.)
- Any condition that requires active medical intervention or monitoring to avert serious danger to the individual s health or wellbeing.
-
Any condition that, in the opinion of the PI, contraindicates participation in this study.
- Additional Exclusion Criteria for Individuals Giving Blood for Research
1. Hemoglobin < 10 g/dL for healthy female volunteers, < 12 g/dL for healthy male volunteers, or < 6 g/dL for participants with sickle cell disease or other chronic anemias.
-Additional Exclusion Criteria for Adipose Tissue Biopsy
Individuals meeting any of the following criteria will be excluded from undergoing adipose tissue biopsy. If the participant no longer meets any of these criteria at a later time, then they will be allowed to undergo this procedure.
- Currently taking anticoagulation medication.
- Platelets < 100,000/microL.
- History of keloid formation (or irregular fibrous tissue formed at the site of a scar or injury).
- History of adverse reactions to lidocaine or other local anesthetics.
Use of aspirin (or acetylsalicylic acid) and nonsteroidal anti-inflammatory drugs (NSAIDs) are permitted.
-Additional Exclusion Criteria for Bronchoscopy
Individuals meeting any of the following criteria will be excluded from undergoing bronchoscopy. If the participant no longer meets any of these criteria at a later time, then they will be allowed to undergo this procedure.
- Prothrombin time (PT) > 1 second above the upper limit of normal (ULN) or international normalized ratio > 1.3.
- Partial thromboplastin time (PTT) > 1 second above ULN.
- Platelets < 150,000/microL.
- Currently taking anticoagulation medication.
- Use of aspirin within 2 weeks of the bronchoscopy or NSAIDs within 2 days of the bronchoscopy.
- Diagnosis of a pulmonary disorder (eg, asthma, chronic bronchitis, cystic fibrosis, or bronchiectasis).
- Respiratory tract infection within the last 4 weeks.
- History of adverse reactions to lidocaine or other local anesthetics.
- History of cigarette smoking within the past 3 months.
- History of chronic opioid use.
- History of drug or alcohol abuse.
- Post-bronchodilator FEV1 < 40% of predicted or pre-bronchodilator FEV1 < 35% of predicted.
- Active bronchospasm on physical examination.
- History of lidocaine allergy.
- Any condition that, in the opinion of the PI, contraindicates this procedure.
Co-enrollment guidelines: Participants may be co-enrolled in other studies. However, the PI must be notified of co-enrollment.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03937817
Contact: Mary J Jackson, R.N. | (301) 761-5667 | alpha.study@nihi.gov | |
Contact: Amy P Ruhl, M.D. | (240) 669-5776 | parker.ruhl@nih.gov |
United States, Maryland | |
National Institutes of Health Clinical Center | Recruiting |
Bethesda, Maryland, United States, 20892 | |
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY dial 711 ccopr@nih.gov |
Principal Investigator: | Amy P Ruhl, M.D. | National Institute of Allergy and Infectious Diseases (NIAID) |
Publications:
Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT03937817 |
Other Study ID Numbers: |
190093 19-I-0093 |
First Posted: | May 6, 2019 Key Record Dates |
Last Update Posted: | January 27, 2023 |
Last Verified: | January 25, 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Plan Description: | .This protocol is not a clinical trial and has no intervention. We do not currently have a plan to share individual participant data (IPD). The IRB-approved data sharing plan in our protocol is as follows: "Identified human data generated in this study will be shared for future research in the Biomedical Translational Research Information System (automatic for activities in the CC). De-identified data may also be shared with outside collaborators under appropriate agreements." |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Assay Development Malaria Sickle Cell Disease Alpha and Beta Thalassemia Natural History |
Malaria Anemia, Sickle Cell Thalassemia beta-Thalassemia Protozoan Infections Parasitic Diseases Infections |
Vector Borne Diseases Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn |